BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Guoli Chen, Zhaohai Yang, James R. Eshleman, George J. Netto, Ming-Tseh Lin. Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectiveBioMed Research International 2016; 2016: 1 doi: 10.1155/2016/9850690
2
Xiaofang Xing, Jianping Guo, Guangyu Ding, Bo Li, Bin Dong, Qin Feng, Shen Li, Jian Zhang, Xiaomin Ying, Xiaojing Cheng, Ting Guo, Hong Du, Ying Hu, Tao Zhou, Xiaohong Wang, Lin Li, Qingda Li, Meng Xie, Liting Li, Xiangyu Gao, Fei Shan, Ziyu Li, Shuqin Jia, Xianzi Wen, Jiping Wang, Jiafu Ji. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patientsOncoImmunology 2018; 7(3): e1356144 doi: 10.1080/2162402X.2017.1356144
3
David J. Birnbaum, François Bertucci, Pascal Finetti, Daniel Birnbaum, Emilie Mamessier. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer 2018; 1869(2): 248 doi: 10.1016/j.bbcan.2018.02.001
4
André F. Oliveira, Luís Bretes, Irene Furtado. Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal CancerFrontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00396
5
Ruiqi Liu, Ke Peng, Yiyi Yu, Li Liang, Xiaojing Xu, Wei Li, Shan Yu, Tianshu Liu. Prognostic Value of Immunoscore and PD-L1 Expression in Metastatic Colorectal Cancer Patients with Different RAS Status after Palliative OperationBioMed Research International 2018; 2018: 1 doi: 10.1155/2018/5920608
6
Yun Tian, Hamzah Abu-Sbeih, Yinghong Wang. ImmunotherapyAdvances in Experimental Medicine and Biology 2018; 995: 151 doi: 10.1007/978-3-030-02505-2_7
7
Apostolos Zaravinos, Constantinos Roufas, Majdi Nagara, Beatriz de Lucas Moreno, Maria Oblovatskaya, Christodoulos Efstathiades, Christos Dimopoulos, Georgios D. Ayiomamitis. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancerJournal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1372-z
8
Zoran Gatalica, Semir Vranic, Joanne Xiu, Jeffrey Swensen, Sandeep Reddy. High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicineFamilial Cancer 2016; 15(3): 405 doi: 10.1007/s10689-016-9884-6
9
Sheik Emambux, Gaelle Tachon, Audelaure Junca, David Tougeron. Results and challenges of immune checkpoint inhibitors in colorectal cancerExpert Opinion on Biological Therapy 2018; 18(5): 561 doi: 10.1080/14712598.2018.1445222
10
Leon Chen, Alexander B. Aria, Sirunya Silapunt, Michael R. Migden. Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin CancerDermatologic Surgery 2019; 45(1): 1 doi: 10.1097/DSS.0000000000001601
11
Minyu Wang, Rita A Busuttil, Sharon Pattison, Paul J Neeson, Alex Boussioutas. Immunological battlefield in gastric cancer and role of immunotherapiesWorld Journal of Gastroenterology 2016; 22(28): 6373-6384 doi: 10.3748/wjg.v22.i28.6373
12
Huan Bin Wang, Han Yao, Chu Shu Li, Lun Xi Liang, Yao Zhang, Ying Xuan Chen, Jing-Yuan Fang, Jie Xu. Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapyJournal of Digestive Diseases 2017; 18(10): 574 doi: 10.1111/1751-2980.12538
13
Esmeralda Celia Marginean, Barbara Melosky. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II—The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal CancerArchives of Pathology & Laboratory Medicine 2018; 142(1): 26 doi: 10.5858/arpa.2017-0041-RA
14
Basile Tessier-Cloutier, Steve E. Kalloger, Mohammad Al-Kandari, Katy Milne, Dongxia Gao, Brad H. Nelson, Daniel J. Renouf, Brandon S. Sheffield, David F. Schaeffer. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinomaBMC Cancer 2017; 17(1) doi: 10.1186/s12885-017-3634-5
15
Lingyu Li, Wei Li, Chang Wang, Xu Yan, Yizhuo Wang, Chao Niu, Xiaoying Zhang, Min Li, Huimin Tian, Cheng Yao, Haofan Jin, Fujun Han, Dongsheng Xu, Wei Han, Dan Li, Jiuwei Cui. Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinomaCytotherapy 2018; 20(1): 134 doi: 10.1016/j.jcyt.2017.09.009
16
Qingfang Zhao, Liang Cao, Lulu Guan, Liangyu Bie, Saiqi Wang, Bojian Xie, Xiaobing Chen, Xiaokun Shen, Feiling Cao. Immunotherapy for gastric cancer: dilemmas and prospectBriefings in Functional Genomics 2019; 18(2): 107 doi: 10.1093/bfgp/ely019
17
Simon Pernot, Toulsie Ramtohul, Julien Taieb. Checkpoint inhibitors and gastrointestinal immune-related adverse eventsCurrent Opinion in Oncology 2016; 28(4): 264 doi: 10.1097/CCO.0000000000000292
18
Petra Hudler, Radovan Komel. Gastric Cancer2017;  doi: 10.5772/intechopen.69775
19
L Liu, Y Wang, R Bai, K Yang, Z Tian. MiR-186 inhibited aerobic glycolysis in gastric cancer via HIF-1α regulationOncogenesis 2016; 5(5): e224 doi: 10.1038/oncsis.2016.35
20
James W.T. Toh, Paul de Souza, Stephanie H. Lim, Puneet Singh, Wei Chua, Weng Ng, Kevin J. Spring. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor TherapyClinical Colorectal Cancer 2016; 15(4): 285 doi: 10.1016/j.clcc.2016.07.007
21
Zheyu Song, Yuanyu Wu, Jiebing Yang, Dingquan Yang, Xuedong Fang. Progress in the treatment of advanced gastric cancerTumor Biology 2017; 39(7): 101042831771462 doi: 10.1177/1010428317714626
22
Junhun Cho, Kyoung-Mee Kim, Hee Cheol Kim, Woo Yong Lee, Won ki Kang, Young Suk Park, Sang Yun Ha. The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinomaPathology - Research and Practice 2019; 215(1): 171 doi: 10.1016/j.prp.2018.10.024
23
Naoki Takahashi, Satoru Iwasa, Yusuke Sasaki, Hirokazu Shoji, Yoshitaka Honma, Atsuo Takashima, Natsuko Tsuda Okita, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancerJournal of Cancer Research and Clinical Oncology 2016; 142(8): 1727 doi: 10.1007/s00432-016-2184-6